Price-to-Projected Revenue Ratio: Impact BioMedical, Inc. (IBO)
Impact BioMedical Inc conducts research on botanical extracts in the US, which determines the dynamics of the future P/S metric. Capitalization is based on patent royalties, although the dispersion of resources creates margin risks. The current status is 1016.10, while this chart demonstrates the current balance of supply and demand, helping to assess the degree of undervaluation or the weakness of this asset.
Analytical breakdowns for impactbiomedinc.com (IBO)
- market price and analyst price targets:
- company stock exchange capitalization indicators:
- book value of equity indicators:
- debt burden and liquidity indicators:
Total Debt to Equity Ratio Impact BioMedical Inc|IBO - Long-Term Loans to Capital Ratio|Short-Term Debt to Equity Ratio Impact BioMedical|IBO - Aggregate Debt Obligations|Debts to Book Capitalization Impact BioMedical Inc|IBO - Company Long-Term Debt|Company Short-Term Debts Impact BioMedical|Quick Liquidity impactbiomedinc.com
- financial results and valuation multiples details:
IBO - Company Net Income|Expected Profit Impact BioMedical Inc|IBO - Price to Earnings Ratio|Forward P/E Multiple Impact BioMedical Inc|IBO - Price to Earnings Adjusted for Growth Rate|EV/EBITDA Multiple Impact BioMedical Inc|IBO - Operating profit before amortization|Net earnings per share (EPS TTM) Impact BioMedical|IBO - Net earnings per share for the last four quarters|Quarterly EPS earnings growth impactbiomedinc.com|IBO - Net earnings per share growth this year|Earnings growth forecast for next year Impact BioMedical Inc
- total revenue and sales volume data:
Summary company analysis:Impact BioMedical Inc IBO
The forward P/S ratio determines the market value of the business relative to expected annual sales, allowing for an assessment of capitalization sensitivity to potential cash gaps. By analyzing the history of the forward P/S valuation, an investor can correlate the growth rates of Impact BioMedical Inc (IBO) with the success of Linebacker antiseptic licensing and the rigor of FDA inspections affecting the company's future revenue.
Who Impact BioMedical Inc competes with
Price-to-Projected Revenue Ratio Haleon HLN|KVUE - Forward Price-to-Revenue Multiple|VRNA - Price-to-Projected Revenue Ratio|Future Price to Revenue MENS|LGND: Forward P/S Multiple|amneal.com (AMRX) - Forward P/S Multiple|PRGO (Perrigo) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Alvotech S.A. (ALVO)|Forward Price-to-Revenue Multiple LQDA (Liquidia Technologies)|Price to Expected Revenue Ratio GLPG|ANI Pharmaceuticals - Forward Price-to-Revenue Multiple|Forward Price to Sales MNKD|Amphastar Pharmaceuticals, Inc. - Forward P/S Multiple|PCRX: Price-to-Projected Revenue Ratio|SPRY: Forward P/S Multiple|TBPH - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Aquestive Therapeutics|Market Cap to Future Revenue Ratio scPharma SCPH|Price-to-Projected Revenue Ratio Tectonic Therapeutic, Inc. (TECX)|Forward Price-to-Revenue Multiple Tonix Pharma TNXP|Forward P/S Multiple SXTC (China SXT Pharmaceuticals, Inc.)|Eupraxia Pharmaceuticals, Inc. (EPRX) - Market Cap to Future Revenue Ratio|BioHarvest Sciences - Forward P/S Multiple|EXOZ (invizyne.com) - Market Cap to Projected Revenue|ORMP: Forward P/S Multiple|ENTX - Market Cap to Expected Sales Ratio|HYFT (MindWalk) - Forward P/S Multiple|Forward Price-to-Revenue Multiple ABVC BioPharma, Inc (ABVC)|Forward P/S Multiple CPIX|Forward P/S Multiple quantumbiopharma.com (QNTM)|Price-to-Projected Revenue Ratio FibroGen FGEN|Telomir Pharmaceuticals Inc - Price-to-Projected Revenue Ratio|RANI: Forward Price-to-Revenue Multiple|Forward Price to Sales SNYR (Synergy CHC Corp)|RLYB: Forward P/S Multiple|LEXX - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Pulmatrix|Market Cap to Projected Revenue PTHL (Pheton)|Forward P/S Multiple APM|Forward Price-to-Revenue Multiple Lyra Therapeutics Inc LYRA|Forward P/S Multiple TNFA (TNF Pharmaceuticals, Inc.)|Market Cap to Expected Sales Ratio cbdMD Inc. (YCBD)|PainReform - Forward P/S Multiple|CYTO: Price-to-Projected Revenue Ratio|Lipella (LIPO) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio OptiNose Corp (OPTN)|Price-to-Projected Revenue Ratio Pieris Pharmaceuticals|procapsgroup.com - Future Price to Revenue|Forward P/S Multiple PTPI|QLI (Qilian International Holding Group) - Forward Price to Sales|Forward P/S Multiple SLRN (ACELYRIN, Inc.)|Forward P/S Multiple TFF Pharmaceuticals, Inc TFFP
